Literature DB >> 17618619

Therapeutic doses of amphetamine and methylphenidate selectively redistribute the vesicular monoamine transporter-2.

Evan L Riddle1, Glen R Hanson, Annette E Fleckenstein.   

Abstract

High-dose administration of psychostimulants traffics the vesicular monoamine transporter-2 (VMAT-2), as assessed by subcellular fractionation of rat striatal tissue. This study demonstrates that administration of low doses of amphetamine or methylphenidate differentially traffic VMAT-2 within nerve terminals, with effects similar to those observed after high-dose administration. Trafficking of vesicular glutamate, acetylcholine, or GABA transporters was not altered by high-or low-dose amphetamine or methylphenidate treatment. These data represent the first report that amphetamine redistributes VMAT-2 protein. In addition, these data demonstrate that the trafficking of VMAT-2 after amphetamine or methylphenidate is selective for monoaminergic neurons.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17618619      PMCID: PMC2581712          DOI: 10.1016/j.ejphar.2007.05.044

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  16 in total

1.  Amphetamine and other psychostimulants reduce pH gradients in midbrain dopaminergic neurons and chromaffin granules: a mechanism of action.

Authors:  D Sulzer; S Rayport
Journal:  Neuron       Date:  1990-12       Impact factor: 17.173

2.  Methamphetamine rapidly decreases vesicular dopamine uptake.

Authors:  J M Brown; G R Hanson; A E Fleckenstein
Journal:  J Neurochem       Date:  2000-05       Impact factor: 5.372

3.  Bupropion increases striatal vesicular monoamine transport.

Authors:  Kristi S Rau; Elisabeth Birdsall; Jarom E Hanson; Kamisha L Johnson-Davis; F Ivy Carroll; Diana G Wilkins; James W Gibb; Glen R Hanson; Annette E Fleckenstein
Journal:  Neuropharmacology       Date:  2005-07-07       Impact factor: 5.250

4.  Comparative studies of various amphetamine analogues demonstrating different interactions with the metabolism of the catecholamines in the brain.

Authors:  J Scheel-Krüger
Journal:  Eur J Pharmacol       Date:  1971       Impact factor: 4.432

5.  Amphetamine neurotoxicity on dopamine nerve terminals in the caudate nucleus of mice.

Authors:  E Nwanze; G Jonsson
Journal:  Neurosci Lett       Date:  1981-10-23       Impact factor: 3.046

6.  Methylenedioxymethamphetamine decreases plasmalemmal and vesicular dopamine transport: mechanisms and implications for neurotoxicity.

Authors:  J Paul Hansen; Evan L Riddle; Verónica Sandoval; Jeffrey M Brown; James W Gibb; Glen R Hanson; Annette E Fleckenstein
Journal:  J Pharmacol Exp Ther       Date:  2002-03       Impact factor: 4.030

7.  Therapeutic doses of amphetamine or methylphenidate differentially increase synaptic and extracellular dopamine.

Authors:  W K Schiffer; N D Volkow; J S Fowler; D L Alexoff; J Logan; S L Dewey
Journal:  Synapse       Date:  2006-03-15       Impact factor: 2.562

8.  Immunoisolation of two synaptic vesicle pools from synaptosomes: a proteomics analysis.

Authors:  Marco Morciano; Jacqueline Burré; Carsten Corvey; Michael Karas; Herbert Zimmermann; Walter Volknandt
Journal:  J Neurochem       Date:  2005-11-03       Impact factor: 5.372

9.  Methylphenidate and pemoline do not cause depletion of rat brain monoamine markers similar to that observed with methamphetamine.

Authors:  R Zaczek; G Battaglia; J F Contrera; S Culp; E B De Souza
Journal:  Toxicol Appl Pharmacol       Date:  1989-09-01       Impact factor: 4.219

10.  Amphetamine redistributes dopamine from synaptic vesicles to the cytosol and promotes reverse transport.

Authors:  D Sulzer; T K Chen; Y Y Lau; H Kristensen; S Rayport; A Ewing
Journal:  J Neurosci       Date:  1995-05       Impact factor: 6.167

View more
  18 in total

Review 1.  The pharmacology of amphetamine and methylphenidate: Relevance to the neurobiology of attention-deficit/hyperactivity disorder and other psychiatric comorbidities.

Authors:  Stephen V Faraone
Journal:  Neurosci Biobehav Rev       Date:  2018-02-08       Impact factor: 8.989

2.  Adverse effects of 2,4-dichlorophenoxyacetic acid on rat cerebellar granule cell cultures were attenuated by amphetamine.

Authors:  B Bongiovanni; A Ferri; A Brusco; M Rassetto; L M Lopez; A M Evangelista de Duffard; R Duffard
Journal:  Neurotox Res       Date:  2010-04-10       Impact factor: 3.911

3.  Exocytosis-related genes and response to methylphenidate treatment in adults with ADHD.

Authors:  B S da Silva; R B Cupertino; D L Rovaris; J B Schuch; D B Kappel; D Müller; C E Bandeira; M M Victor; R G Karam; N R Mota; L A Rohde; V Contini; E H Grevet; C H D Bau
Journal:  Mol Psychiatry       Date:  2017-05-02       Impact factor: 15.992

Review 4.  Psychostimulant-induced alterations in vesicular monoamine transporter-2 function: neurotoxic and therapeutic implications.

Authors:  Annette E Fleckenstein; Trent J Volz; Glen R Hanson
Journal:  Neuropharmacology       Date:  2008-07-10       Impact factor: 5.250

5.  Method development and validation of an in vitro model of the effects of methylphenidate on membrane-associated synaptic vesicles.

Authors:  Trent J Volz; Sarah J Farnsworth; Glen R Hanson; Annette E Fleckenstein
Journal:  J Neurosci Methods       Date:  2008-10-17       Impact factor: 2.390

Review 6.  Illicit dopamine transients: reconciling actions of abused drugs.

Authors:  Dan P Covey; Mitchell F Roitman; Paul A Garris
Journal:  Trends Neurosci       Date:  2014-03-20       Impact factor: 13.837

7.  The spontaneously hypertensive and Wistar Kyoto rat models of ADHD exhibit sub-regional differences in dopamine release and uptake in the striatum and nucleus accumbens.

Authors:  Erin M Miller; Francois Pomerleau; Peter Huettl; Vivienne A Russell; Greg A Gerhardt; Paul E A Glaser
Journal:  Neuropharmacology       Date:  2012-09-01       Impact factor: 5.250

8.  Methylphenidate-induced increases in vesicular dopamine sequestration and dopamine release in the striatum: the role of muscarinic and dopamine D2 receptors.

Authors:  Trent J Volz; Sarah J Farnsworth; Shane D Rowley; Glen R Hanson; Annette E Fleckenstein
Journal:  J Pharmacol Exp Ther       Date:  2008-06-30       Impact factor: 4.030

9.  Amphetamine augments vesicular dopamine release in the dorsal and ventral striatum through different mechanisms.

Authors:  Alicia J Avelar; Steven A Juliano; Paul A Garris
Journal:  J Neurochem       Date:  2013-03-06       Impact factor: 5.372

10.  Cocaine alters vesicular dopamine sequestration and potassium-stimulated dopamine release: the role of D2 receptor activation.

Authors:  Sarah J Farnsworth; Trent J Volz; Glen R Hanson; Annette E Fleckenstein
Journal:  J Pharmacol Exp Ther       Date:  2008-11-26       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.